Impax Laboratories Inc  

(Public, NASDAQ:IPXL)   Watch this stock  
Find more results for IPXL
0.00 (0.00%)
Sep 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 7.75 - 27.29
Open     -
Vol / Avg. 0.00/1.46M
Mkt cap 1.77B
P/E     -
Div/yield     -
EPS -8.08
Shares 74.31M
Beta 1.17
Inst. own 91%
Nov 7, 2017
Q3 2017 Impax Laboratories Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 25, 2017
Impax Laboratories Inc at Cantor Fitzgerald Global Healthcare Conference - 2:25PM EDT - Add to calendar
Sep 12, 2017
Impax Laboratories Inc at Morgan Stanley Healthcare Conference - Webcast
Aug 9, 2017
Q2 2017 Impax Laboratories Inc Earnings Release
Aug 9, 2017
Q2 2017 Impax Laboratories Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -10.10% -57.26%
Operating margin -4.74% -64.83%
EBITD margin - -48.28%
Return on average assets -4.82% -25.21%
Return on average equity -15.36% -55.98%
Employees 1,495 -
CDP Score - -


30831 Huntwood Ave
HAYWARD, CA 94544-7003
United States - Map
+1-510-2406000 (Phone)
+1-510-2406096 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Officers and directors

Robert L. Burr Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Paul M. Bisaro President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Bryan M. Reasons Chief Financial Officer, Senior Vice President - Finance
Age: 49
Bio & Compensation  - Reuters
Douglas S. Boothe President - Generics Division
Age: 53
Bio & Compensation  - Reuters
Michael J. Nestor President - Impax Specialty Pharmaceutical Division
Age: 64
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq. Senior Vice President, General Counsel, Corporate Secretary
Age: 56
Bio & Compensation  - Reuters
Jeffrey D. Nornhold Senior Vice President - Technical Operations
Age: 51
Bio & Compensation  - Reuters
J. Kevin Buchi Director
Age: 61
Bio & Compensation  - Reuters
Janet S. Vergis Director
Age: 52
Bio & Compensation  - Reuters
Leslie Z. Benet Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters